substernal chest pain, which had developed three hour prior to presentation. No previous cardiac history was reported. She was hemodynamically stable and her cardiovascular examination was unremarkable. An electrocardiogram (ECG) showed ≥0.2 mV ST segment elevation in leads II, III, aVF and reciprocal ST depression in lead I, aVL along with R wave and 0.1mV ST depression & upright-T wave in leads V1 and V2. ST segment elevation of 0.1 mV was also present in lead V4R. ECG findings were consistent with infero-posterior STEMI with right ventricular infarction (Fig 1 a & b) . The patient was given aspirin (loading dose of 300 mg orally) & clopidogrel (loading dose of 600 mg orally) with intention of PPCI. Cardiac enzyme (CK-MB: 32 U/L, troponin-I: 0.68 ng/mL) was elevated. Serum creatinine level was 2.9 mg/dl with eGFR of 16.93 ml/min/1.73m 2 . Two-dimensional echocardiogram revealed akinesia in the RCA territories. A diagnostic coronary angiogram (CAG) through transradial approach showed thrombotic total occlusion in the mid RCA without collateral flow (Fig 2) . There was non-obstructive disease in left anterior descending and left circumflex arteries. A 6 Fr JR 3.5 guiding catheter was used to cannulate RCA. A 0.014 inch ASAHI SION blue Guidewire (ASAHI INTECH, Japan) was passed across the occlusion successfully & TIMI 0/1 flow was achieved. After low pressure pre-dilatation with a 2.5×15 mm Sapphire II balloon (OrbusNeich), large thrombus burden was evidence in distal RCA (Fig 3) & thrombi were aspirated using 6 Fr DIVER CEMAX catheter (INVATEC, The patient remained free of adverse cardiac events & was discharged home at day 4 with preserved left ventricular ejection fraction (LVEF) & slight hypokinesia in inferior wall.
Discussion:
Acute myocardial infarction (AMI) is considered to be related primarily to the rupture or erosion of a coronary atherosclerotic plaque. This initiates intraluminal thrombus formation superimposed on the ruptured plaque which leads to total or subtotal occlusion of an epicardial coronary artery. 5 PPCI has emerged as the preferred treatment of AMI if logistically feasible and has been proven to be a very effective method to obtain patency of IRA. 6 Distal embolization is a possible complication of PPCI; in these patients, a microvascular injury occurs, which finally leads to a lack of myocardial reperfusion. Thrombus aspiration during PPCI has been proposed to prevent embolization. 7 Although the use of thrombectomy devices to aspirate thrombus during PPCI is currently not used routinely, there is growing evidence suggesting the use of thrombus aspiration catheters during PCI. This case highlights the effectiveness of using devices like the aspiration catheter in the setting of STEMI in restoring flow in IRA.
Manual thrombectomy devices that are currently in clinical use include the Export® Catheter (Metronic, USA), Diver® (Invatec, Italy), Hunter (IHT Cordynamics, Spain), Pronto® (Vascular solutions, USA), QuickCat (Spectranetics Inc., USA) and Eliminate (Terumo) amongst others. Although these devices are similar, there are differences in the way the thrombus is extracted. 7 The ESC and ACC/AHA guidelines recommend coronary artery thrombus aspiration as adjunctive therapy during PPCI for STEMI. 8, 9 Thrombus aspiration is endorsed as a class IIa recommendation with the level of evidence B in the ACC/AHA guideline 8 and with level of evidence A in the ESC guidelines. 9 A number of clinical trials have assessed the use of manual thrombectomy in STEMI. One of the first randomised PPCI trials that tested a manual aspiration device was the REMEDIA (Randomised Evaluation of the Effect of Mechanical Reduction of Distal Embolisation by Thrombus Aspiration in Primary and Rescue Angioplasty) study (Diver ®). This study randomised 99 patients to PCI with manual aspiration or PPCI only. 10 This study demonstrated that manual aspiration was associated with significantly better STR and MBG as well as reduced distal embolisation and reduced no reflow. In addition, a subgroup analysis demonstrated that thrombus aspiration was more beneficial in patients with an occluded artery and those with higher thrombus burden. 10 De Luca et al. found that using manual thrombectomy in patients with anterior STEMI (n = 76), demonstrated better post procedural MBG and better STR at 90 minutes. 11 In a Bayesian meta-analysis by Mongeon et al., which included 21 trials totalling 4,299 patients (16 trials that used simple aspiration thrombectomy device), thrombectomy was shown to result in more STR and TIMI 3 flow. 12 
TAPAS (Thrombus Aspiration During Percutaneous
Coronary Intervention in Acute Myocardial Infarction Study) was the largest trial to date in 2008. TAPAS was a single-centre randomised trial that recruited 1,071 patients with STEMI and randomised 535 patients to manual aspiration using the Export® catheter compared to 535 patients randomised to PPCI alone. 13 Patients in the thrombectomy arm had higher MBG, higher STR and fewer pathological Q-waves. Moreover, the study showed a significant reduction in mortality with thrombus aspiration at 1 year. 14 After TAPAS, a number of trials have confirmed the evidence of the benefits of manual thrombectomy. In the EXPIRA (Thrombectomy With export Catheter in Infarct-Related Artery During Primary Percutaneous Coronary Intervention) trial, 175 patients were recruited with MBG and STR as primary end points. This trial was the first study to assess thrombectomy use with microvascular obstruction as a primary end-point. MACE (Major Adverse Cardiac Events) at 9 months was the secondary end point. 15 The study demonstrated that manual thrombectomy significantly improved both MBG and STR and reduced final infarct size (as assessed by MRI). In addition, manual thrombectomy was associated with reduced cardiac morality and MACE at 24 month followup. 15 This case also showed that manual thrombectomy via transradial approach following acute infero-posterior STEMI had better post procedural MBG & better STR as well as improved in-hospital clinical outcome.
In conclusion, manual thrombectomy may be an effective and safe option for the treatment of very high thrombotic lesions in patients with acute STEMI.
